Stock of the Day

September 24, 2020

Charles River Laboratories International (CRL)

$224.19
-$4.97 (-2.2%)
Market Cap: $11.04B

About Charles River Laboratories International

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Today's Trend

Charles River Laboratories International, Inc. (NYSE: CRL) is getting a lift from a series of bullish analyst revisions. Zacks Research raised earnings estimates across multiple future periods, including FY2026, FY2027, and several quarterly forecasts, signaling improving profit expectations for the medical research company. That kind of upward estimate revision can support the stock because it suggests analysts see stronger future earnings than before.

  • Zacks Research increased its FY2026 EPS estimate for Charles River Laboratories International to $10.91 from $10.79, implying slightly better near-term earnings power.
  • The firm also lifted FY2027 EPS forecasts to $12.11 from $11.62 and raised several quarterly estimates, including Q2 2027, Q3 2027, Q4 2027, and Q1 2028, reinforcing a more optimistic longer-term outlook.
  • Zacks Research raised Q2 2026, Q3 2026, and Q4 2026 earnings estimates as well, suggesting momentum may be improving across the next several reporting periods.
  • Brokerage sentiment remains constructive overall, with the stock previously noted as having a consensus “Moderate Buy” rating.
  • Recent market commentary also pointed to a 5% share-price surge earlier this week, adding to already positive trading momentum.

Overall, CRL appears to be moving higher because analysts are marking up earnings expectations across 2026–2028, which tends to improve investor confidence in future growth and valuation.

← Previous Stock of the DayNext Stock of the Day →

Recent News